The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB APPROVAL Washington, D.C. 20549 OMB Number: 3235-0076 FORM D Estimated average burden hours per response: 4.00 Notice of Exempt Offering of Securities 1. Issuer's Identity Previous CIK (Filer ID Number) None Entity Type Names 0001689375 CycloPorters, Inc. X Corporation Limited Partnership Name of Issuer Entrada Therapeutics, Inc. Limited Liability Company Jurisdiction of Incorporation/Organization **General Partnership** DELAWARE **Business Trust** Year of Incorporation/Organization Other (Specify) Over Five Years Ago Х Within Last Five Years (Specify Year) 2016 Yet to Be Formed 2. Principal Place of Business and Contact Information Name of Issuer Entrada Therapeutics, Inc. Street Address 1 Street Address 2 c/o Foley Hoag LLP 155 Seaport Blvd. City State/Province/Country ZIP/PostalCode Phone Number of Issuer MASSACHUSETTS 02210-2600 857-305-1825 Boston 3. Related Persons Last Name First Name Middle Name Tartaglia Louis Street Address 1 Street Address 2 c/o Foley Hoag LLP 155 Seaport Blvd. City State/Province/Country ZIP/PostalCode Boston MASSACHUSETTS 02210-2600 Relationship: Executive Officer X Director Promoter Clarification of Response (if Necessary): Last Name First Name Middle Name Parmar Kush Street Address 1 Street Address 2 c/o Foley Hoag LLP 155 Seaport Blvd. City State/Province/Country ZIP/PostalCode MASSACHUSETTS 02210-2600 Boston Relationship: Executive Officer X Director Promoter Clarification of Response (if Necessary): Last Name First Name Middle Name Pei Dehua Street Address 1 Street Address 2 c/o Foley Hoag LLP 155 Seaport Blvd. City State/Province/Country ZIP/PostalCode MASSACHUSETTS 02210-2600 Boston Relationship: Executive Officer X Director Promoter Clarification of Response (if Necessary):

Street Address 1	Street Address 2				
c/o Foley Hoag LLP	155 Seaport Blvd.				
City	State/Province/Country	ZIP/PostalCode			
Boston	MASSACHUSETTS	02210-2600			
Relationship: Executive Officer X Director	r Promoter				
Clarification of Response (if Necessary):					
Last Name	First Name	Middle Name			
Doshi	Dipal				
Street Address 1	Street Address 2				
c/o Foley Hoag LLP	155 Seaport Blvd.				
City	State/Province/Country	ZIP/PostalCode			
Boston	MASSACHUSETTS	02210-2600			
Relationship: X Executive Officer X Director	Promoter				
Clarification of Response (if Necessary):					
Last Name	First Name	Middle Name			
Sethuraman	Natarajan				
Street Address 1	Street Address 2				
c/o Foley Hoag LLP	155 Seaport Blvd.				
City	State/Province/Country	ZIP/PostalCode			
Boston	MASSACHUSETTS	02210-2600			
Relationship: X Executive Officer Director	r Promoter				
Clarification of Response (if Necessary):					
4. Industry Group					
Agriculture	Health Care	Retailing			
Banking & Financial Services	Biotechnology	Restaurants			
Commercial Banking	Health Insurance				
Insurance					
Investing	Hospitals & Physicians	Computers			
Investment Banking	X Pharmaceuticals	Telecommunications			
Pooled Investment Fund	Other Health Care	Other Technology			
Ls the issuer registered as	Manufacturing	Travel			
an investment company under	Real Estate	—			
the Investment Company		Airlines & Airports			
Act of 1940?		Lodging & Conventions			
	Construction	Tourism & Travel Services			
Other Banking & Financial Services	REITS & Finance				
Business Services	Residential	Other Travel			
Energy		Other			
Coal Mining	Other Real Estate				
Electric Utilities					
Energy Conservation					
Environmental Services					
Oil & Gas					
Other Energy					
5. Issuer Size					
	Aggregate Not As 1	Velue Perge			
Revenue Range OR	Aggregate Net Asset	-			
	No Aggregate Net	ASSEL VALUE			
\$1 - \$1,000,000		1 \$5,000,000			
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000			
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000			
\$25,000,001 - \$100,000,000	\$50,000,001 - \$10	\$50,000,001 - \$100,000,000			
Over \$100,000,000	Over \$100,000,00	0			

X Decline to Disclose	Decline to Disclose							
6. Federal Exemption(s) and Exclusion(s) Claimed								
_		any Act Section $3(c)$						
Rule 504(b)(1) (not (i), (ii) or (iii))	Section $3(c)(1)$	Section 3(c)(9)						
Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii)	Section 3(c)(2)	Section 3(c)(10)						
Rule 504 (b)(1)(iii)	Section 3(c)(3)	Section 3(c)(11)						
X Rule 506(b)	Section 3(c)(4)	Section 3(c)(12)						
Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)						
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)						
	Section 3(c)(7)							
7. Type of Filing								
X New Notice Date of First Sale 2018-12-14 First	st Sale Yet to Occur							
Amendment								
8. Duration of Offering								
Does the Issuer intend this offering to last more than o	one year? XYes No							
9. Type(s) of Securities Offered (select all that app	ly)							
X Equity		Pooled Investment Fund Interests						
Debt		Tenant-in-Common Securities						
Option, Warrant or Other Right to Acquire Another Security to be Acquired Upon Exercise of Option, V		Mineral Property Securities						
to Acquire Security		Other (describe)						
10. Business Combination Transaction								
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?								
Clarification of Response (if Necessary):								
11. Minimum Investment								
Minimum investment accepted from any outside invest	tor \$0 USD							
12. Sales Compensation								
Recipient	Recip	ent CRD Number X None						
(Associated) Broker or Dealer X None	(Asso	ciated) Broker or Dealer CRD Numbe	er X None					
Street Address 1		Address 2 Province/Country	ZIP/Postal Code					
City State(s) of Solicitation (select all that apply)	1 —	-	ZIF/FUSIal Code					
Check ấ€œAll States†or check individual States _		reign/non-US						
13. Offering and Sales Amounts								
Total Offering Amount \$59,021,750 USD or Ir	ndefinite							
Total Amount Sold \$34,021,752 USD								
Total Remaining to be Sold \$24,999,998 USD or Ir	ndefinite							
Clarification of Response (if Necessary):								
Total Offering Amount and Total Amount Sold include the additional closings.	conversion of outstanding in	debtedness of the Issuer. A portion of th	e offering amount is reserved for					
14. Investors								
Select if securities in the offering have been or main number of such non-accredited investors who alreed the second seco			rs, and enter the					
Regardless of whether securities in the offering has enter the total number of investors who already has a security of the total number of investors who already has a security of the total number of tot	ave been or may be sold	o persons who do not qualify as acc	redited investors, 10					

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD	Estimate
Finders' Fees \$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$645,000 USD X Estimate

Clarification of Response (if Necessary):

The above figure is an estimate of payments for services in the ordinary course expected to be made over the course of one year.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Entrada Therapeutics, Inc.	/s/ Dipal Doshi	Dipal Doshi	President & CEO	2018-12-22

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.